Cannabis Law Report

OCTOBER 10, 2021

We at Cantourage share the belief that cannabis is a valuable medicine which until now has not gained enough attention as a therapy option. Provide guidance on clinical trials and plays integral role in bringing new product innovations to different markets in Europe (and beyond). Customized compensation package.

Clinical Trials 52

Clinical Trials Therapy Medicine Pharmaceutical 52

Cannabis Law Report

APRIL 21, 2022

MAPS PBC is pioneering new forms of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for post-traumatic stress disorder (PTSD). MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD.

Advocacy 52

Advocacy Therapy Clinical Trials Pharmaceutical 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Holiday Pay.

Therapy 40

Therapy Compliance Compliance Clinical Trials 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

OCTOBER 29, 2019

Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.

Safety 45

Safety CBD Clinical Trials Oil 45

Cannabis Law Report

SEPTEMBER 21, 2021

And regulators need to be thinking in the best interests of consumers who rely on plant-based therapies for their health and quality of life. If we are going to provide medicinal cannabis opportunities covered by insurance, we need the ability to go through clinical trials and testing. No, they need to be re-reviewed.

Environment 52

Environment Pharmaceutical Retail Clinical Trials 52

Cannabis Law Report

DECEMBER 30, 2019

For the first time, the FY 2020 Appropriations package contained this protection for 47 states within the base language of the text. Included in the final FY 2020 spending package). Specifically, it expands the pool of patients eligible for cannabis therapy to include those with chronic pain, menstrual cramps, and epilepsy.

Legislation 59

Legislation Patients Access Banking 59

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. References.

Pharmaceutical 73

Pharmaceutical Extraction CBD Epilepsy 73